Clinical trial · Observational
The Relapses in Childhood Acute Lymphoplastic Leukemia Excluding L3
The Relapses in Childhood Acute Lymphoplastic Leukemia Excluding L3: Experience of Single Institute/ Baghdad
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background: acute lymphoblastic leukemia is the most common childhood cancer and relapse is the main reason for treatment failure in childhood acute lymphoblastic leukemia. The aim of this study: is to assess the relapse of childhood acute lymphoblastic leukemia in pediatric patients treated in the Child's Central Teaching Hospital/ Baghdad. Methods: A retrospective study that reviewed 521 children with newly diagnosed ALL for children below 15 years during the period from 1st of January 2013 to 1st of March 2020 in the hemato-oncology ward in the Child's Central Teaching Hospital in Baghdad, with a total duration of follow-up for two years post last starting treatment (till 1st of March 2022 ).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Acute | Acute Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- relapse group
- label
- non-relapse group
Primary outcomes (1)
- measure
- the relapse of childhood acute lymphoblastic leukemia in pediatric patients treated in the Child's Central Teaching Hospital/ Baghdad
- timeFrame
- the period from 1st of January 2013 to 1st of March 2020
- description
- 521 children reviewed with newly diagnosed ALL for children below 15 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Months
- Maximum age
- 15 Years
Show eligibility criteria text
Inclusion Criteria: * patients diagnosed with acute lymphoplastic leukemia Exclusion Criteria: * patients died before starting induction chemotherapy. * patients referred to another oncological center. * those who starting the treatment in another oncological center
References
Publications (0)
Data not yet available